Pharma BD Deal Intelligence
Multi-leg asset swap between GSK and Novartis announced April 22, 2014. Leg 1: GSK acquired Novartis vaccines business (excluding flu vaccines) for $7.1B. Leg 2: Novartis acquired GSK oncology portfolio (including marketed and pipeline assets) for $16B. Leg 3: GSK and Novartis combined their consumer healthcare businesses into a new joint venture (GSK 63.5%, Novartis 36.5%). Total deal value approximately $20B+. The swap fundamentally reshaped both companies strategic profiles, with GSK doubling down on vaccines/consumer and Novartis concentrating on innovative pharmaceuticals.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| GSK plc / Novartis AG (this deal) | 2014 | $16.0B | 76 |
| GSK plc / SmithKline Beecham | 2000 | $12.0B | 79 |
| GSK plc / Pfizer Inc. | 2018 | $0.0M | 77 |
| GSK plc / Hansoh Pharmaceutical Group Co. Ltd. | 2023 | $1.7B | 74 |
| GSK plc / Nuvalent, Inc. | 2026 | $10.6B | 70 |
| GSK plc / Sierra Oncology Inc. | 2022 | $1.9B | 70 |
| GSK plc / Human Genome Sciences | 2012 | $3.6B | 70 |
← Browse all deals · How we score deals
More: 2014 deals · GSK plc deals · Oncology deals